Sanofi SA
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
E: investor.relations@sanofi.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,594.10 | 7.40 | 0.09% |
| CAC 40 | 7,734.40 | 130.04 | -1.65% |
| DAX 40 | 23,629.58 | 369.59 | -1.54% |
| Dow JONES (US) | 41,603.07 | 256.02 | -0.61% |
| FTSE 100 | 8,717.97 | 21.29 | -0.24% |
| HKSE | 23,366.06 | 235.20 | -1.00% |
| NASDAQ | 18,737.21 | 188.53 | -1.00% |
| Nikkei 225 | 37,432.61 | 272.14 | 0.73% |
| NZX 50 Index | 12,543.07 | 53.43 | -0.42% |
| S&P 500 | 5,802.82 | 39.19 | -0.67% |
| S&P/ASX 200 | 8,364.80 | 3.90 | 0.05% |
| SSE Composite Index | 3,338.42 | 9.95 | -0.30% |